Edwards Lifesciences (NYSE:EW) Issues FY 2026 Earnings Guidance

by · The Cerbat Gem

Edwards Lifesciences (NYSE:EW – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.800-2.950 for the period, compared to the consensus estimate of 2.860. The company issued revenue guidance of $6.4 billion-$6.8 billion, compared to the consensus revenue estimate of $6.6 billion.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $85.02 on Thursday. The firm has a 50 day moving average of $80.54 and a 200-day moving average of $78.63. Edwards Lifesciences has a 12 month low of $65.94 and a 12 month high of $87.40. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $49.33 billion, a PE ratio of 36.57, a PEG ratio of 3.78 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Mizuho boosted their price objective on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Truist Financial raised their price target on shares of Edwards Lifesciences from $87.00 to $90.00 and gave the stock a “hold” rating in a report on Monday, November 3rd. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research report on Monday, November 3rd. Citigroup boosted their target price on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, UBS Group reiterated a “neutral” rating on shares of Edwards Lifesciences in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $91.39.

Check Out Our Latest Research Report on EW

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.29% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $25,000. Rakuten Securities Inc. grew its holdings in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Kelleher Financial Advisors purchased a new stake in shares of Edwards Lifesciences in the third quarter worth about $50,000. Chapman Financial Group LLC bought a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $63,000. Finally, Financial Life Planners bought a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $93,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

See Also